

1 **Persistent HBV replication and serological response during up to fifteen years of tenofovir-based**  
2 **antiretroviral therapy in HIV-hepatitis B coinfecting patients: a multicenter prospective cohort study**

3

4 **Running title:** Fifteen years of tenofovir in HIV-HBV coinfection

5

6 Lorenza N. C. Dezanet<sup>1</sup>, Patrick Mialhes<sup>2</sup>, Caroline Lascoux-Combe<sup>3</sup>, Julie Chas<sup>4</sup>, Sarah Maylin<sup>5</sup>, Audrey

7 Gabassi<sup>5,6</sup>, Hayette Rougier<sup>7</sup>, Constance Delaugerre<sup>5,6</sup>, Karine Lacombe<sup>1,8</sup>, Anders Boyd\*<sup>8</sup>

8

9 **Institutional affiliations:**

10 <sup>1</sup>Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, F75012,  
11 Paris, France

12 <sup>2</sup>Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Service de Maladies Infectieuses et Tropicales, Lyon,  
13 F69317, France

14 <sup>3</sup>APHP, Hôpital Saint-Louis, Service de Maladies Infectieuses, Paris, F75010, France

15 <sup>4</sup>APHP, Hôpital Tenon, Service de Maladies Infectieuses, Paris, F75020, France

16 <sup>5</sup>APHP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, F75010, France

17 <sup>6</sup>Université de Paris, INSERM U944, Institut de Recherche Saint-Louis, F75010, Paris, France

18 <sup>7</sup>IMEA, Institut de Médecine et d'Epidémiologie Appliquée, Paris, F75018, France

19 <sup>8</sup>APHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, F75012, France

20

21 **\*Corresponding author:**

22 Dr. Anders Boyd

23 Services de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine

24 184 Rue du Faubourg St. Antoine, 75571 Paris Cedex 12, France

25 Tel: +33 1 71 97 05 17

26 Fax: +33 1 49 28 21 49

27 Email: [unders.boyd@iplesp.upmc.fr](mailto:anders.boyd@iplesp.upmc.fr)

28

29 **Abstract**

30 **Objectives**

31 To determine the extent of hepatitis B virus (HBV) suppression and its association with hepatitis “e” antigen  
32 (HBeAg) and hepatitis B surface antigen (HBsAg)-seroclearance in HIV-HBV-coinfected patients undergoing  
33 long-term tenofovir (TDF)-based antiretroviral therapy (ART).

34 **Methods**

35 We prospectively followed 165 HIV-HBV-coinfected patients undergoing TDF-based ART. Serum HBV-DNA  
36 viral loads, HBeAg and HBsAg were obtained at TDF-initiation and every 6-12 months. We calculated the  
37 proportion achieving virological response (VR, <60 IU/mL) during follow-up. We also calculated rates of  
38 HBeAg- and HBsAg-seroclearance, which were compared between those who achieved versus never  
39 achieved VR during follow-up using an exact binomial test.

40 **Results**

41 During a median 8.1 years (IQR=4.0-13.2) of TDF-treatment, 152 (92.1%) patients were able to achieve VR  
42 and 13 (7.9%) never achieved VR (median HBV-DNA at the end of follow-up=608 IU/mL, range=67-  
43 52,400,000). The prevalence of individuals with detectable HBV-DNA ( $\geq 60$  IU/mL) decreased during TDF-  
44 treatment: 15.1% ( $n=14/93$ ) at 5-years, 3.2% ( $n=2/62$ ) at 10-years and, 3.2% ( $n=1/31$ ) at 15-years. 44/96  
45 HBeAg-positive patients (6.15/100 person-years) had HBeAg-seroclearance and 13/165 patients overall  
46 (0.87/100 person-years) had HBsAg-seroclearance. No difference in HBeAg-seroclearance was observed  
47 between those who achieved versus never achieved VR (7.4 versus 3.7/100 person-years,  $p=0.33$ ), while  
48 HBsAg-seroclearance was only observed in those with VR (1.0 versus 0/100 person-years,  $p=0.49$ ;  
49 respectively). Individuals with VR also had a higher frequency of undetectable HIV-RNA during treatment  
50 ( $p<0.001$ ).

51 **Conclusions**

52 During long-term TDF-based ART for HIV-HBV coinfection, persistent HBV viremia is apparent, but becomes  
53 less frequent over time. HBsAg-seroclearance only occurred in those with full HBV and relatively high HIV  
54 suppression.

## 55 Introduction

56 In the past decade, liver-related mortality has continued to persist as one of the major causes of non-AIDS  
57 related deaths in HIV-positive patients.<sup>1,2</sup> Coinfection with hepatitis B virus (HBV) has been implicated as a  
58 major reason for this finding.<sup>3</sup> HBV infection by itself is associated with an increased risk of liver fibrosis  
59 progression, cirrhosis and hepatocellular carcinoma (HCC), which can be mitigated with effective HBV-DNA  
60 suppression.<sup>4</sup> Given that tenofovir (TDF) has dual activity against HIV and HBV, long-term administration of  
61 TDF-containing antiretroviral therapy (ART) has been recommended for all HIV-HBV coinfecting patients.<sup>5,6</sup>

62

63 Although TDF has a high genetic barrier to HBV resistance,<sup>7</sup> at least 3 years of treatment may be required to  
64 achieve virological response,<sup>8-10</sup> while 10-20% of HIV-HBV coinfecting patients exhibit persistence of HBV  
65 replication during longer periods of TDF.<sup>8,11-13</sup> Nevertheless, almost all studies to date evaluating HBV  
66 replication during TDF have followed patients for at most 5-10 years and consequently, it is uncertain what  
67 proportion of patients achieve suppression of HBV-DNA viral load with longer TDF-use.<sup>8,14</sup>

68

69 There are other therapeutic goals for improved prognosis, such as hepatitis B “e” antigen (HBeAg)-  
70 seroclearance (for those with HBeAg-positive serology) and importantly, hepatitis B surface antigen  
71 (HBsAg)-seroclearance. For TDF-treated HIV-HBV coinfecting patients, almost half of those who are HBeAg-  
72 positive exhibit HBeAg-seroclearance and few overall attain HBsAg-seroclearance.<sup>8,15,16</sup> Since HBeAg-  
73 seroclearance and HBsAg-seroclearance seem to only occur among HIV-HBV coinfecting individuals  
74 undergoing TDF with sustained HBV virological response,<sup>8</sup> there is concern regarding the consequences of  
75 persistent HBV replication on serological outcomes. Most of our understanding on HBV seroclearance rates  
76 also stems from studies of HIV-HBV coinfecting and HBV-monoinfecting patients with limited duration of TDF  
77 treatment.<sup>8,14</sup>

78

79 In this study, we aimed to evaluate the extent of HBV suppression and determinants of various forms of HBV  
80 persistence in patients coinfecting with HIV-HBV undergoing up to 15 years of continuous TDF-based ART.

81 We further intended to examine the relationship between HBV persistence and HBeAg- and HBsAg-  
82 seroclearance.

83

## 84 **Patients and Methods**

### 85 ***Study population***

86 Patients were selected from the French HIV-HBV Cohort Study.<sup>17</sup> Briefly, this longitudinal cohort study  
87 included 308 HIV-positive patients with chronic HBV infection from four centers located in Paris and Lyon,  
88 France. Patients were included if they had HIV-positive serological results confirmed by western blot and  
89 HBsAg-positive serological results for >6 months. Participants were recruited in 2002-2003 and followed up  
90 prospectively every 6-12 months until 2017-2018. The cohort design and procedures are described  
91 elsewhere.<sup>17,18</sup>

92

93 For this analysis, we included patients undergoing TDF-containing ART for  $\geq 24$  consecutive months. This  
94 timeframe was chosen since studies in HBV mono-infection and HIV-HBV coinfection have demonstrated that  
95 >90% achieve virological response within 24 months of nucleos(t)ide analogue (NA) therapy.<sup>19</sup> We did not  
96 include patients with concomitant interferon/pegylated interferon (peg-IFN) or detectable hepatitis C virus  
97 (HCV) or hepatitis D virus (HDV) RNA.

98

### 99 ***Ethics***

100 All patients provided written informed consent to participate in the study and the protocol was approved by  
101 the appropriate ethics committee (Paris, France) in accordance with the Helsinki Declaration.<sup>17</sup>

102

### 103 ***Data collection***

104 Demographic information was collected at study inclusion. HIV-related variables included HIV-RNA viral load  
105 (HIV-VL) and CD4<sup>+</sup> cell count, and were collected before TDF-initiation and at each follow-up visit. HBV-  
106 related variables included HBV-DNA VL, alanine aminotransferase (ALT) levels, aspartate aminotransferase

107 (AST) levels, qualitative HBeAg, anti-HBe antibodies, HBsAg, and anti-HBs antibodies, and were collected  
108 before TDF-initiation and at each follow-up visit. Cumulative exposure to viral replication was calculated  
109 using time-averaged copy-years over follow-up time ( $\text{copy-years}_{\text{TAVG}}$ ), as detailed elsewhere.<sup>18</sup> At TDF-  
110 initiation, L-nucleoside-associated HBV mutations at positions rt173, rt180, and rt204 of the *pol* gene and at  
111 nucleotide 1896 of the *precore* gene were determined using DNA chip technology (bioMérieux, Marcy  
112 l’Etoile, France).<sup>20</sup> Liver fibrosis was assessed at each yearly interval by the FibroTest® calculated from a  
113 standard battery of biochemical markers.<sup>21</sup> METAVIR equivalents of this measure, as established in the HIV-  
114 HBV coinfecting population, were used to grade liver fibrosis ( $F2=0.48-0.58$ ,  $F3=0.59-0.73$ ,  $F4\geq 0.74$ ).<sup>22</sup>

115

### 116 ***HBV replication profiles***

117 HBV replication profiles were based on HBV-viral load (VL) at the end of the follow-up, as defined  
118 previously.<sup>8</sup> First, patients were classified on whether or not they had undetectable HBV-VL at the last  
119 follow-up visit (HBV-DNA <60 IU/mL). Second, those with undetectable HBV-VL were divided into two  
120 subgroups: sustained virological response (sustained-VR; achieving and/or constantly maintaining HBV-DNA  
121 <60 IU/mL thereafter) or transient persistent viremia (PV; attaining <60 IU/mL, intermittently  $\geq 60$  IU/mL  
122 thereafter and returning to undetectable levels at the last visit). Patients with detectable HBV-VL at the last  
123 visit were divided into two subgroups: low-level persistent viremia (LL-PV; 60-2,000 IU/mL) or high-level  
124 persistent viremia (HL-PV; >2,000 IU/mL).

125

### 126 ***Statistical analysis***

127 Baseline was defined as the study visit at or directly before TDF-initiation. Follow-up began at TDF-initiation  
128 and continued until the last study visit, TDF-discontinuation, initiating peg-IFN, detection of HCV or HDV  
129 RNA, or death, whichever occurred first.

130

131 We used several sets of endpoints to evaluate HBV-DNA suppression. First, the percentage with  
132 undetectable HBV-DNA was calculated at the end of each yearly interval of follow-up. Second, the

133 cumulative proportion achieving VR (HBV-DNA <60 IU/mL) was calculated during continuous time. Third, in  
134 the subset of patients who had achieved VR, we identified visits at which HBV-DNA VL was detectable  
135 ( $\geq 60$ /mL) after achieving VR [i.e. viral persistence]. Risk-factor analysis for viral persistence was performed  
136 on this subset of patients using follow-up that began at the first undetectable HBV-DNA VL and continued  
137 until right-censoring. Univariable odds ratios (OR) comparing the odds across levels of determinants over  
138 time and their 95% confidence intervals (95%CI) were calculated from a logistic regression model, which  
139 included a random-intercept to account for between-patient variation at baseline. A multivariable model  
140 was constructed by adding all covariables with a  $p$  value <0.20 in univariable analysis and removing  
141 nonsignificant variables in backward-stepwise fashion. Finally, we constructed HBV replication profiles as  
142 defined above. Comparisons between HBV replication profiles were performed for all clinical parameters at  
143 baseline and during follow-up using the Kruskal-Wallis test for continuous variables and Pearson's  $\chi^2$  test or  
144 Fisher's exact test for categorical variables. Scatterplots and locally weighted scatterplot smoothing plots  
145 were used to illustrate the evolution of HBV-DNA replication according to HBV replication profiles.

146

147 We then used HBeAg-seroclearance (for HBeAg-positive patients) and HBsAg-seroclearance as endpoints.  
148 We estimated the cumulative proportion achieving these events, while only considering the first  
149 seroclearance event and not taking into account transitioning back to antigen-positive status. We estimated  
150 time to seroclearance using Kaplan-Meier curves and the incidence of seroclearance rates, which were  
151 compared between those who achieved versus never achieved VR using a two-sided Exact binomial test with  
152 mid-p assumption.

153

154 All statistical analyses were performed using STATA software (v15.1; College Station, Texas, USA) and  
155 significance was determined using a  $p$  value < 0.05.

156

## 157 **Results**

### 158 ***Description of the study population***

159 Of the 308 patients included in the cohort, 143 were not included in analysis for the following reasons: did  
160 not initiate TDF ( $n=51$ ), used TDF for less than 24 months ( $n=42$ ), used concomitant PEG-IFN or IFN ( $n=20$ ),  
161 ever had anti-HCV and/or anti-HDV antibody positive serology ( $n=23$ ), or had insufficient information at  
162 baseline ( $n=7$ ). Thus, 165 individuals were included in the present analysis (Supplementary Figure 1).

163

164 Of these 165 patients, most were male (83.6%) with a median age of 41.7 years (IQR=36.4-48.3) at TDF-  
165 initiation (Table 1). Almost all patients had previously initiated ART (99.4%), with a median 7.0 years of ART  
166 exposure (IQR=4.4-9.2), and thus median CD4+ count was  $410/\text{mm}^3$  (IQR=288-596) and 97 (58.8%) had  
167 undetectable HIV-RNA. At baseline, 96 (58.2%) patients were HBeAg-positive and HBV-DNA was detectable  
168 in 75.2% of participants. Of the 147 patients (89.1%) with previous lamivudine (LAM) exposure, median LAM  
169 duration was 5.1 years (IQR=2.8-6.8) at TDF initiation and, among those with available information, 20/100  
170 (20.0%) had baseline LAM resistance mutations. HBV genotype was determined in 105 patients, and most  
171 harbored genotype A (67.6%), followed by G (15.2%), E (8.6%) and D (8.6%). Among patients with available  
172 data on Fibrotest scores at TDF initiation ( $n=147$ ), 36 (24.5%) had F3-F4 fibrosis.

173

#### 174 ***HBV-DNA suppression during TDF-containing ART***

175 Patients were followed for a median 8.1 years (IQR=4.0-13.2), with a maximum follow-up of 15.7 years.  
176 Three patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) based ART during  
177 follow-up, while follow-up during TAF was still included in analysis (median TAF duration: 0.5 years,  
178 range=0.2-5.6). The percentage of patients with undetectable HBV-DNA increased substantially in the first 6  
179 years of TDF treatment, while, thereafter, ranging between 94.0-97.8% and never reaching 100% (Figure 1a).

180

181 163 (98.8%) patients were able to achieve virological response after a median 0.90 years (IQR=0.39-1.74) of  
182 follow-up and of them, 30 (18.2%) had at least one visit with detectable HBV-DNA after achieving virological  
183 response. The number of visits with detectable HBV-DNA for these patients were distributed as follows: 1,  
184  $n=17$ ; 2,  $n=7$ ; 3,  $n=2$ ; 4,  $n=2$ ; 10,  $n=1$ ; and, 18,  $n=1$ . Risk factors for viral persistence over time are given in

185 Table 2. In multivariable analysis, positive HBeAg status at baseline ( $p=0.04$ ), lower nadir CD4+ cell counts  
186 ( $p=0.002$ ) and undetectable HIV-VL ( $p<0.001$ ) were significantly associated with viral persistence.

187

188 We then characterized HBV replication profiles based on HBV-VLs at the end of follow-up. Of the 152  
189 (92.1%) patients with undetectable HBV-VL, 133 (87.5%) had remained undetectable (sustained-VR) and 19  
190 (12.5%) had become detectable (median peak HBV-VL=2.54  $\log_{10}$  IU/mL, range=1.79-8.04) after having  
191 achieved undetectable HBV-VL (transient-PV). Among those with transient-PV, 10 had more than one visit  
192 with detectable HBV-DNA, with the time from first to last detectable HBV DNA measurement lasting a  
193 median 1.0 year (range=0.12-7.0). Of the 13 (7.9%) patients with detectable HBV-VL at the end of the follow-  
194 up, 9 had LL-PV (median HBV-VL=272 IU/mL, range=67-1,341) and 4 had HL-PV (range HBV-VL=3.91-7.72  
195  $\log_{10}$  IU/mL). Of these patients, 11 had achieved HBV-VL <60 at least once during follow-up (LL-PV,  $n=8$ ; HL-  
196 PV,  $n=3$ ). The proportion of patients with undetectable HBV-VLs are summarized between groups in Figure  
197 1b, while changes in HBV-VLs are given for patients with sustained-VR in Figure 1c, transient-PV in Figure 1d  
198 and LL-/HL-PV in Figure 1e.

199

200 At baseline, patients with transient-PV profile, as compared to sustained-VR, were significantly more likely to  
201 be HBeAg-positive ( $p=0.04$ ), to have detectable HIV-VL ( $p=0.04$ ), lower nadir CD4+ cell count ( $p=0.002$ ),  
202 higher BMI ( $p=0.01$ ), and shorter cumulative LAM treatment prior to TDF-initiation ( $p=0.03$ ) (Table 3).  
203 Patients with LL-/HL-PV profiles had significantly higher baseline ALT ( $p=0.007$ ) and AST levels ( $p=0.03$ ),  
204 when compared to those with either sustained-VR or transient-PV. During follow-up, patients with  
205 sustained-VR profile, compared to transient-PV, were significantly more likely to achieve virological response  
206 at 24 months of therapy ( $p=0.03$ ), showed higher frequency of suppressed HIV-VL ( $p<0.001$ ) and lower  
207 frequency of liver fibrosis progression from mild or moderate fibrosis (F0-F1-F2) to more advanced fibrosis  
208 (F3-F4;  $p=0.04$ ) (Table 4). When including only individuals with two or more visits with detectable HBV-DNA  
209 (after VR) in the transient-PV group, similar differences between groups were observed (data not shown).  
210 Individuals with LL-/HL-PV profiles, when compared to all other profiles, were significantly more likely to

211 have shorter duration of follow-up ( $p<0.001$ ), higher 12-month ( $p<0.001$ ) and 24-month change ( $p<0.001$ ) in  
212 HBV-VL, higher maximum decrease ( $p<0.001$ ) and increase ( $p<0.001$ ) of ALT levels from baseline, and higher  
213 ALT levels at the last follow-up visit ( $p<0.001$ ). Moreover, individuals with LL-/HL-PV profiles, compared to  
214 sustained-VR, had a lower frequency of undetectable HIV-VL for all visits during follow-up (Table 4).

215

#### 216 ***HBeAg- and HBsAg-seroclearance and its relation to viral persistence during TDF-containing ART***

217 Of the 96 HBeAg-positive patients at study inclusion, 44 lost HBeAg (cumulative incidence: 45.8%;  
218 95%CI=35.6%-56.3%) after a median 4.9 years (IQR=3.0-9.0) of follow-up (incidence rate=6.1/100 person-  
219 years). Of them, 2 reverted back to HBeAg-positive serology and 4 changed serostatus multiple times until  
220 ending follow-up with HBeAg-negative serology. Of the 42 patients ending follow-up with HBeAg-negative  
221 serology, acquisition of anti-HBe antibodies (anti-HBeAb) was achieved in 14 (33.3%) patients either at the  
222 same visit as HBeAg-seroclearance ( $n=10$ ) or from 1.7-11.4 years after HBeAg-seroclearance ( $n=4$ ). Of these  
223 patients, 6 (42.9%) lost anti-HBeAb by the end of follow-up.

224

225 No difference was observed in HBeAg-seroclearance between those who were able to achieve VR during  
226 follow-up versus those who never achieved VR (7.4 versus 3.7/100 person-years respectively,  $p=0.33$ , Figure  
227 2a). Of those who had HBeAg-seroclearance, 34 belonged to the sustained-VR, 8 transient-PV profile, and 2  
228 LL-PV groups.

229

230 A total of 13 patients lost HBsAg (cumulative incidence: 7.9%; 95%CI=4.3%-13.1%) after a median 7.5 years  
231 (IQR=3.8-11.2) of follow-up (incidence rate=0.9/100 person-years). Of these patients, two reverted back to  
232 HBsAg-positive serology and one changed serostatus multiple times until ending follow-up with HBsAg-  
233 positive serology. Of the 10 patients ending follow-up with HBsAg-negative serology, acquisition of anti-  
234 HBsAb was achieved in six (60.0%) either at the same visit as HBsAg-seroclearance ( $n=3$ ) or from 0.9-6.7  
235 years after HBsAg-seroclearance ( $n=3$ ). Additionally, 6 patients who lost HBsAg were HBeAg-positive at

236 baseline. For these patients, median time from HBeAg-seroclearance to HBsAg-seroclearance was 4.8 years  
237 (range=0.5-13.5).

238

239 HBsAg-seroclearance was only observed in those who achieved VR, yet this rate was not significantly  
240 different from those who were never able to achieve VR (1.0 versus 0/100 person-years, respectively,  
241  $p=0.49$ , Figure 2b). Of those who had HBsAg-seroclearance, 11 belonged to the sustained-VR and 2  
242 transient-PV profile groups.

243

#### 244 ***Severe liver-related morbidity and mortality and its relation to viral persistence during TDF-containing ART***

245 At TDF initiation, 4 patients had already experienced a severe liver-related event [portal hypertension n=1;  
246 HCC, n=2; haemorrhagic necrosis of liver, n=1]. Of them, 2 had sustained VR, 1 had transient PV and 1 had  
247 HL-PV. During TDF treatment, 3 patients developed portal hypertension (all with sustained VR profiles), 1  
248 hepatorenal syndrome (HL-PV profile), 3 HCC (2 with sustained VR and 1 with LL-PV profiles), and 2  
249 haemorrhagic necrosis of liver (1 with sustained VR and 1 with transient PV). Two deaths were the result of  
250 HCC (1 with sustained VR and 1 with LL-PV profile) and one from decompensated liver with HCC and  
251 complications due to septic shock (sustained-VR profile). All three patients who developed HCC during  
252 follow-up had METAVIR F3-F4 fibrosis at TDF initiation, as measured by the FibroTest®. Ultrasound revealed  
253 the presence of hepatic nodules for all three patients, along with steatosis (n=2) and portal vein thrombosis  
254 (n=1).

255

#### 256 **Discussion**

257 Using longitudinal data from one of the longest studies to date on TDF-use in HIV-HBV coinfecting individuals,  
258 we observed that viral persistence continues to occur throughout TDF-treatment, with 18.2% of patients  
259 exhibiting detectable HBV-DNA after having achieved virological response. Nevertheless, the probability of  
260 having detectable HBV-DNA decreased as the duration of TDF increased and  $\leq 6\%$  of patients consistently  
261 had detectable HBV-DNA every year after 6 years of TDF. These data support the durability of HBV

262 suppression associated with TDF-use and suggest that viral persistence does not mitigate long-term viral  
263 suppression.

264

265 The extent of persistent viremia in individuals with chronic HBV infection varies considerably across studies.  
266 When defining persistence based on HBV-DNA levels at a maximum 24 months of follow-up, we found that  
267 only 8% of patients presented with LL-/HL-PV. If minimum follow-up is extended to 60 months, where most  
268 HIV-HBV coinfecting individuals appeared to have achieved HBV virological suppression, only 4% of patients  
269 had LL-PV and no patient had HL-PV. The proportion of patients with HBV persistence in our study is  
270 considerably lower when compared to other prospective studies in HIV-HBV coinfecting, reporting 14% to  
271 54%.<sup>8,9,12</sup> However, these studies used inability to achieve virological response at 12-months as the basis for  
272 persistent viremia, which, given our data and others,<sup>9</sup> is too short a timeframe to define persistence. When  
273 defining persistence based on any detection of HBV-VL after achieving VR, we found that 20% of individuals  
274 had at one point persistent viremia. In the GS-US-174-0102 and GS-US-174-0103 registration studies in HBV  
275 mono-infected patients, this type of persistence occurred very rarely (0.9%).<sup>23</sup>

276

277 We observed that median CD4<sup>+</sup> cell count at last follow-up visit and the frequency of undetectable HIV-VL  
278 over time were significantly higher in patients with sustained-VR compared to other profiles, while patients  
279 who had higher CD4<sup>+</sup> counts for longer periods of time were able to more frequently suppress HBV-DNA  
280 replication after achieving initial virological response. Indeed, immunosuppression as an underlying factor  
281 for viral persistence has been evoked in other studies.<sup>12,15</sup> Previous research has suggested that HIV-HBV  
282 coinfecting patients have lower levels of HBV-specific CD4<sup>+</sup> T-cell responses,<sup>24,25</sup> intrahepatic T cells, Kupfer  
283 cells and NK cells,<sup>26</sup> as well as reduced intrahepatic inflammatory activity when compared to HIV-positive  
284 patients without HBV infection. Taken together, these data highlight the importance of immunoregulation to  
285 control HBV replication and could explain why persistence occurs more frequently in HIV-HBV coinfecting  
286 versus HBV mono-infected patients.

287

288 Detectable HIV-RNA viremia was also more often observed during treatment for individuals with transient-  
289 PV, LL- and HL-PV profiles and was strongly associated with HBV viral persistence after achieving virological  
290 response. Similar findings have been observed by others.<sup>9,12</sup> In general, detectable HIV-RNA, as determined  
291 by most commercial assays, is either due to developing HIV resistant variants or inadequate adherence to  
292 ART.<sup>27</sup> Given that no consistent mutation pattern for TDF resistance has yet to be observed,<sup>4</sup> detectable  
293 HBV-DNA would likely be the result of poor adherence.<sup>28</sup> Much of the concordance of simultaneously  
294 detectable HIV-RNA and HBV-DNA would then likely be the result of insufficient adherence. We did not  
295 collect data on HIV resistance and our data on HBV sequences are limited to the first 8 years of follow-up,  
296 hence we are unable to confirm this speculation. TDF plasma concentrations were indeed lower or even  
297 undetectable for individuals with profiles of LL/HL-PV in our previous study,<sup>8</sup> while others have found lower  
298 concentrations of intracellular drug levels of tenofovir-diphosphate, a measure of long-term adherence, for  
299 HIV-HBV coinfecting individuals with HBV persistent viremia during TDF-treatment.<sup>29</sup> Nevertheless,  
300 considering that HIV-RNA was undetectable for 71% of visits when HBV-VL was detectable (after initial HBV  
301 virological response), adherence alone cannot fully explain HBV persistent viremia.

302

303 For individuals with persistent viremia, it is clear that the vast majority are able to eventually suppress HBV-  
304 DNA. It remains debatable to what extent persistent viremia leads to major long-term serological  
305 consequences. We observed that individuals with LL- and HL-PV profiles were never able to achieve HBsAg-  
306 seroclearance. The reasons for this finding are not entirely clear. Large rebounds in HBV-DNA replication  
307 have been shown to be associated with HBsAg-seroclearance, but is usually accompanied with ALT flares and  
308 occurs mostly in HBV treatment cessation studies or during the course of natural infection,<sup>30,31</sup> increases in  
309 ALT levels were rarely observed during HBV viral persistence in our study population of TDF-treated  
310 individuals. It could be that ability to achieve sustained VR is a proxy for tighter control of HBV viral activity  
311 in general; however, further evidence would be needed to confirm this finding. Nevertheless, it should be  
312 noted that only 7.9% of the entire study population were able to exhibit HBsAg-seroclearance, even after up

313 to 15 years of follow-up. The lack of function cure would appear to be more a general problem in treated  
314 coinfecting patients.

315

316 The clinical consequences of persistent HBV viremia are also fairly unknown. From several studies during the  
317 natural history of chronic HBV infection, consistently high levels of HBV-DNA (i.e.  $\geq 10,000$  copies/mL) during  
318 later phases of HBV infection are mostly associated with developing HCC and cirrhosis.<sup>32</sup> Expectedly, our  
319 data showed a low incidence of clinical liver-related outcomes, with no strong evidence that PV *per se* is  
320 associated with higher rates of liver-related morbidity and mortality.

321

322 This study has several strengths, including possibly the longest follow-up to date in either HIV-HBV  
323 coinfecting<sup>8,9,13,18</sup> and HBV-monoinfecting patients<sup>14,33</sup> with consistently measured virological and serological  
324 markers of HBV. However, certain limitations need to be addressed. First, the time-dependent definitions of  
325 HBV replications profiles might be inadequate for under 3 years of follow-up. Therefore, we decided to also  
326 use persistent viremia after initial VR as a complementary definition of persistence. Second, we did not  
327 measure plasma TDF concentrations to assess adherence, so we cannot determine if those patients with  
328 viral persistence were adherent to ART or whether a decrease in frequency of persistence was due to  
329 improved adherence over time. Third, our data represent a population that is highly ART-experienced and  
330 more immunosuppressed compared to contemporary patient populations, but still actively seen in  
331 outpatient settings. Finally, since genotypic data were not collected at later years of TDF use in our cohort,  
332 we are unable to determine whether viral persistence is related to certain mutational patterns.<sup>34</sup> From our  
333 last analysis, there were only 9 additional patients exhibiting an HBV-VL  $> 1000$  IU/mL, which would be ideal  
334 for sequencing, and the small numbers would unlikely reveal any other mutation patterns explaining viral  
335 persistence during TDF use.

336

337 In conclusion, we demonstrate that TDF is able to suppress HBV-DNA to undetectable levels in the majority  
338 of ART-experienced HIV-HBV coinfecting patients undergoing up to 15 years of TDF-containing ART.

339 Nevertheless, a low proportion of patients do exhibit HBV viral persistence. A small proportion of patients  
340 achieved HBV functional cure, which was exclusively observed in those with sustained HBV-VLs. This low  
341 percentage of serological responders is quite similar to HBV mono-infected patients undergoing prolonged  
342 TDF treatment<sup>14</sup> and highlights the need to identify novel HBV treatment strategies against HBV. Still,  
343 evaluating the relationship between HBV persistent viremia and more severe clinical outcomes is warranted  
344 in larger, longitudinal cohort studies.  
345

346 **Acknowledgements**

347 The authors are grateful to the patients and the clinical teams for their commitment to the French HIV-HBV  
348 Cohort. This study was sponsored by the Institut de Médecine et d'Epidémiologie Appliquée (IMEA). L.N.C.D.  
349 was awarded a post-doctoral fellowship from the France REcherche Nord&sud Sida-hiv Hépatites (ANRS).

350

351 **Role of each author.** L.N.C.D. was responsible for the statistical analysis, interpretation of the data, and  
352 drafting the manuscript. S.M., A.G. and C.D. were responsible for interpretation of the data and drafting the  
353 manuscript. H.R., P.M., C. L-C., and J.C. acquired data for the cohort, assisted in interpreting data, and gave  
354 critical revisions of the manuscript. K.L. helped design, conceptualize, and obtain funding for the French HIV-  
355 HBV cohort study, coordinated data collection, and drafted parts of the manuscript. A.B. coordinated data  
356 analysis, gave important comments on data interpretation, drafted the manuscript, and provided critical  
357 revisions of the manuscript. All authors approved the final version.

358

359 **Funding**

360 This study was supported by SIDACTION (AO 19) and the ANRS. Gilead Sciences, Inc. provided an  
361 unrestricted grant for the French HIV-HBV cohort and was not involved in any part of the design, data  
362 collection, analysis and manuscript writing.

363

364 **Transparency declarations**

365 None to declare.

366

367 **Supplementary Data**

368 Figure S1 is available as Supplementary data.

369

370 **References**

- 371 1. Morlat P, Roussillon C, Henard S, *et al.* Causes of death among HIV-infected patients in France in 2010  
372 (national survey): trends since 2000. *AIDS* 2014; **28**: 1181–91.
- 373 2. Sellier P, Hamet G, Brun A, *et al.* Mortality of People Living with HIV in Paris Area from 2011 to 2015. *AIDS*  
374 *Res Hum Retroviruses* 2020; **36**: 373–80.
- 375 3. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, *et al.* Factors  
376 associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. *AIDS* 2010; **24**:  
377 1537–48.
- 378 4. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the  
379 management of hepatitis B virus infection. *J Hepatol* 2017; **67**: 370–98.
- 380 5. European AIDS Clinical Society. *EACS Guidelines version 10.1*. European AIDS Clinical Society.  
381 <https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>
- 382 6. Price H, Dunn D, Pillay D, *et al.* Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A  
383 Systematic Review and Meta-Analysis Ahn S-H, ed. *PLoS ONE* 2013; **8**: e68152.
- 384 7. Liu Y, Corsa AC, Buti M, *et al.* No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and  
385 HBeAg– patients with chronic hepatitis B after 8 years of treatment. *J Viral Hepat* 2017; **24**: 68–74.
- 386 8. Boyd A, Gozlan J, Maylin S, *et al.* Persistent viremia in human immunodeficiency virus/hepatitis B  
387 coinfecting patients undergoing long-term tenofovir: Virological and clinical implications. *Hepatology* 2014;  
388 **60**: 497–507.
- 389 9. Hafkin JS, Osborn MK, Localio AR, *et al.* Incidence and risk factors for incomplete HBV DNA suppression in  
390 HIV/HBV-co-infected patients initiating tenofovir-based therapy. *J Viral Hepat* 2014; **21**: 288–96.
- 391 10. Huang AJ, Núñez M. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected  
392 by Immune Suppression. *J Int Assoc Provid AIDS Care* 2015; **14**: 360–8.
- 393 11. Audsley J, Bent SJ, Littlejohn M, *et al.* Effects of long-term tenofovir-based combination antiretroviral  
394 therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B  
395 virus quasispecies diversity: *AIDS* 2016; **30**: 1597–606.

- 396 12. Matthews GV, Seaberg EC, Avihingsanon A, *et al.* Patterns and Causes of Suboptimal Response to  
397 Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus. *Clin Infect Dis* 2013; **56**:  
398 e87–94.
- 399 13. de Vries–Sluijs TEMS, Reijnders JGP, Hansen BE, *et al.* Long-term Therapy With Tenofovir Is Effective for  
400 Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus. *Gastroenterology* 2010;  
401 **139**: 1934–41.
- 402 14. Marcellin P, Wong DK, Sievert W, *et al.* Ten-year efficacy and safety of tenofovir disoproxil fumarate  
403 treatment for chronic hepatitis B virus infection. *Liver Int* 2019; **39**: 1868–75.
- 404 15. Huang Y-S, Sun H-Y, Chang S-Y, *et al.* Long-term virological and serologic responses of chronic hepatitis B  
405 virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B  
406 coinfection. *Hepatol Int* 2019; **13**: 431–9.
- 407 16. Boyd A, Maylin S, Moh R, *et al.* Hepatitis B surface antigen quantification as a predictor of seroclearance  
408 during treatment in HIV-hepatitis B virus coinfecting patients from Sub-Saharan Africa: Seroclearance during  
409 treatment. *J Gastroenterol Hepatol* 2016; **31**: 634–44.
- 410 17. Boyd A, Dezanet LNC, Kassime R, *et al.* Subclinical and Clinical Outcomes in Patients Coinfected With HIV  
411 and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective,  
412 Longitudinal Cohort Study. *JMIR Res Protoc* 2021; **10**: e24731.
- 413 18. Boyd A, Gozlan J, Miaillhes P, *et al.* Rates and determinants of hepatitis B ‘e’ antigen and hepatitis B  
414 surface antigen seroclearance during long-term follow-up of patients coinfecting with HIV and hepatitis B  
415 virus: *AIDS* 2015; **29**: 1963–73.
- 416 19. Marcellin P, Zoulim F, Hézode C, *et al.* Effectiveness and Safety of Tenofovir Disoproxil Fumarate in  
417 Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. *Dig Dis Sci* 2016; **61**: 3072–83.
- 418 20. Lacombe K, Boyd A, Lavocat F, *et al.* High incidence of treatment-induced and vaccine-escape hepatitis B  
419 virus mutants among human immunodeficiency virus/hepatitis B-infected patients. *Hepatology* 2013; **58**:  
420 912–22.
- 421 21. Poynard T, Ngo Y, Munteanu M, Thabut D, Ratzu V. Noninvasive Markers of Hepatic Fibrosis in Chronic

- 422 Hepatitis B. *Curr Hepatitis Rep* 2011; **10**: 87–97.
- 423 22. Bottero J, Lacombe K, Guéchet J, *et al.* Performance of 11 biomarkers for liver fibrosis assessment in  
424 HIV/HBV co-infected patients. *J Hepatology* 2009; **50**: 1074–83.
- 425 23. Gordon SC, Krastev Z, Horban A, *et al.* Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients  
426 with chronic hepatitis B with high baseline viral load. *Hepatology* 2013; **58**: 505–13.
- 427 24. Chang JJ, Wightman F, Bartholomeusz A, *et al.* Reduced hepatitis B virus (HBV)-specific CD4+ T-cell  
428 responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active  
429 antiretroviral therapy. *J Virol* 2005; **79**: 3038–51.
- 430 25. Chang JJ, Sirivichayakul S, Avihingsanon A, *et al.* Impaired quality of the hepatitis B virus (HBV)-specific T-  
431 cell response in human immunodeficiency virus type 1-HBV coinfection. *J Virol* 2009; **83**: 7649–58.
- 432 26. Iser DM, Avihingsanon A, Wisedopas N, *et al.* Increased intrahepatic apoptosis but reduced immune  
433 activation in HIV-HBV co-infected patients with advanced immunosuppression. *AIDS* 2011; **25**: 197–205.
- 434 27. Panel on Antiretroviral Guidelines for Adults and Adolescents. *Guidelines for the Use of Antiretroviral*  
435 *Agents in Adults and Adolescents with HIV*. Department of Health and Human Services.  
436 <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf>
- 437 28. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. *J Hepatology* 2012; **56**:  
438 S112–22.
- 439 29. Wong TC, Lan A, Kiser JJ, *et al.* Novel quantification of tenofovir disoproxil fumarate adherence in human  
440 immunodeficiency virus/hepatitis B coinfecting patients with incomplete hepatitis B virus viral suppression.  
441 *Hepatology* 2016; **64**: 999–1000.
- 442 30. Avihingsanon A, Matthews GV, Lewin SR, *et al.* Assessment of HBV flare in a randomized clinical trial in  
443 HIV/HBV coinfecting subjects initiating HBV-active antiretroviral therapy in Thailand. *AIDS Res Ther* 2012; **9**:  
444 6.
- 445 31. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically  
446 mediated liver disease. *Gastroenterology* 2001; **120**: 1009–22.
- 447 32. Chen C-J, Yang H-I. Natural history of chronic hepatitis B REVEALed. *J Gastroenterol Hepatol* 2011; **26**:

448 628–38.

449 33. Buti M, Fung S, Gane E, *et al.* Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated  
450 with tenofovir disoproxil fumarate for up to 5 years. *Hepatol Int* 2015; **9**: 243–50.

451 34. Park E-S, Lee AR, Kim DH, *et al.* Identification of a quadruple mutation that confers tenofovir resistance in  
452 chronic hepatitis B patients. *J Hepatology* 2019; **70**: 1093–102.

453

**Table 1.** Baseline characteristics among HIV/hepatitis B virus cohort participants (N=165).

Characteristic	N (%) or median (IQR)
Demographics	
Gender, male/female (% male)	138/25 (83.6)
Age, years*	41.7 (36.4-48.3)
BMI $\geq$ 25 Kg/m <sup>2</sup> , N=149*	27 (18.1)
Born in high HBV endemic zone <sup>†</sup>	45 (27.3)
HIV characteristics	
Ever having an AIDS-defining illness <sup>†</sup>	41 (24.9)
Known HIV infection duration, years*	11.1 (7.10-15.0)
Detectable HIV-RNA <sup>†</sup>	68 (41.2)
HIV-RNA <sup>‡</sup> , log <sub>10</sub> copies/mL*	4.1 (2.9-4.6)
CD4 <sup>+</sup> cell count, per mm <sup>3</sup> , N=164*	410 (288-596)
CD4 <sup>+</sup> nadir cell count, per mm <sup>3</sup> , N=152*	224 (104-319)
Duration of prior ART, years, N=164*	7.0 (4.4-9.2)
Viral hepatitis B characteristics	
Known HBV infection duration, years, N=164*	8.3 (4.2-12.1)

Prior LAM exposure <sup>†</sup>	147 (89.1)
Cumulative prior LAM treatment, years, N=147*	5.1 (2.8-6.8)
LAM-resistant mutations, N=100 <sup>†</sup>	20 (20.0)
Detectable HBV-DNA <sup>†</sup>	124 (75.2)
HBV-DNA <sup>‡</sup> , log <sub>10</sub> IU/mL*	5.2 (3.2-7.2)
HBeAg-positive <sup>†</sup>	96 (58.2)
ALT, IU/L, N=161*	40 (26-68)
AST, IU/L, N=161*	34 (25-56)
F3-F4 fibrosis <sup>#</sup> , N=147 <sup>†</sup>	36 (24.5)
<i>Precore</i> mutations, N=101 <sup>†</sup>	22 (21.8)
HBV genotype, N=105 <sup>†</sup>	
A	71 (67.6)
D	9 (8.6)
E	9 (8.6)
G	16 (15.2)

---

\*Median (IQR).

<sup>†</sup> Number (%).

<sup>#</sup> Estimated using the FibroTest®.

Abbreviations: AIDS, acquired immune deficiency syndrome; ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMI, body mass index; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HBeAg, hepatitis B “e” antigen; LAM, lamivudine.

**Table 2.** Determinants of viral persistence ( $\geq 60$  IU/mL) after having achieved virological response ( $N=163$ ).

	Univariable			Multivariable <sup>b</sup>	
	<i>N</i> <sup>a</sup>	OR (95% CI)	<i>p</i> value	aOR (95% CI)	<i>p</i> value
Age at baseline, years	163	0.97 (0.91-1.04)	0.4		
Male gender	163	3.05 (0.54-17.35)	0.21		
High HBV-endemic zone	163	0.42 (0.11-1.58)	0.20		
BMI					
At baseline	147	1.06 (0.86-1.30)	0.6		
$\geq 25$ Kg/m <sup>2</sup> at baseline	147	3.04 (0.79-11.76)	0.11		
During follow-up*	160	0.94 (0.90-0.99)	0.02		
Ever having an AIDS-defining illness	163	2.56 (0.73-8.92)	0.14		
Nadir CD4 <sup>+</sup> cell count (v/mm <sup>3</sup> )	150	0.84 (0.75-0.93)	0.001	0.86 (0.78-0.95)	0.002
CD4 <sup>+</sup> cell count (v/mm <sup>3</sup> )					
At baseline	162	0.88 (0.80-0.97)	0.01		
During follow-up*	163	0.99 (0.98-1.01)	0.30		
Undetectable HIV-RNA ( $\leq 50$ copies/mL)	163	0.25 (0.12-0.55)	0.001	0.23 (0.10-0.51)	<0.001
HIV-RNA, log <sub>10</sub> copies/mL <sup>‡</sup>	70	1.08 (0.58-2.00)	0.8		
HIV infection duration at baseline, years	163	0.98 (0.88-1.10)	0.7		

Duration of prior ART at baseline, years	163	0.95 (0.81-1.11)	0.5		
HBV infection duration at baseline, years	162	0.95 (0.86-1.06)	0.4		
Baseline HBV-DNA, log <sub>10</sub> IU/mL <sup>‡</sup>	122	1.05 (0.77-1.42)	0.8		
HBeAg-positive					
At baseline	163	4.28 (1.24-14.71)	0.02	3.41 (1.08-10.78)	0.04
During follow-up*	163	0.97 (0.82-1.15)	0.7		
Previous LAM treatment	163	1.85 (0.27-12.69)	0.5		
Baseline LAM-resistant mutations	98	0.61 (0.08-4.53)	0.6		
Baseline <i>precore</i> mutations	99	1.53 (0.33-7.16)	0.6		
ALT >35 IU/mL					
At baseline	159	0.27 (0.08-0.93)	0.04		
During follow-up*	163	0.88 (0.76-1.03)	0.11		
AST >35 IU/mL					
At baseline	159	0.38 (0.12-1.20)	0.10		
During follow-up*	163	0.87 (0.74-1.02)	0.08		
F3-F4 fibrosis <sup>#</sup>	145	0.72 (0.19-2.73)	0.6		

\*Time-dependent variables.

‡ Among patients with detectable HIV-RNA or HBV-DNA viral loads.

# Estimated using the Fibrotest®.

<sup>a</sup> Total number of patients in analysis.

<sup>b</sup> BMI during follow-up was not considered in multivariable analysis because BMI <25, ≥ 25 Kg/m<sup>2</sup> at baseline was preferred. All ORs are adjusted for the variables listed in the column.

Abbreviations: AIDS, acquired immune deficiency syndrome; ALT, alanine aminotransferase; aOR, adjusted OR; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMI, body mass index; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HBeAg, hepatitis B “e” antigen; LAM, lamivudine.

**Table 3.** Baseline characteristics of hepatitis B virus replication profiles.

Characteristics	Sustained VR (N=133)	Transient PV (N=19)	LL-/HL-PV (N=13)	p value <sup>§</sup>
<b>Demographics</b>				
Gender, male/female (% male)	109/24 (82.0)	16/3 (84.2)	13/0 (100)	NS
Age, years*	42.3 (37.2-49.2)	39.7 (33.8-43.9)	39.8 (34.7-44.9)	NS
BMI, Kg/m <sup>2</sup> , N=149*	22.3 (20.7-24.1)	23.7 (22.5-26.0)	22.2 (20.9-23.9)	1
Born in high HBV endemic zone <sup>†</sup>	38 (28.6)	5 (26.3)	2 (15.4)	NS
<b>HIV characteristics</b>				
Ever having an AIDS-defining illness <sup>†</sup>	30 (22.6)	8 (42.1)	3 (23.1)	NS
Known HIV infection duration, years*	11.3 (6.3-15.0)	10.1 (7.1-13.1)	10.2 (7.6-12.2)	NS
Detectable HIV-RNA <sup>†</sup>	51 (38.3)	12 (63.2)	5 (38.5)	1
HIV-RNA <sup>‡</sup> , log <sub>10</sub> copies/mL*	3.7 (2.7-4.4)	4.4 (3.9-4.7)	4.3 (4.1-4.6)	NS
CD4 <sup>+</sup> cell count, per mm <sup>3</sup> , N=164*	440 (334-601)	262 (115-379)	500 (212-754)	1,3
CD4 <sup>+</sup> nadir cell count, per mm <sup>3</sup> , N=152*	238 (130-333)	121 (34-179)	96 (56-286)	1
Duration of prior ART, years, N=164*	7.0 (4.4-9.2)	7.6 (4.1-8.5)	6.4 (4.8-8.3)	NS

Viral hepatitis B characteristics

Known HBV infection duration, years, <i>N</i> =164*	8.3 (4.3-12.3)	9.3 (3.7-10.8)	6.1 (2.8-13.1)	NS
Prior LAM exposure <sup>†</sup>	118 (88.7)	16 (84.2)	13 (100)	NS
Cumulative prior LAM treatment, years, <i>N</i> =142*	5.5 (3.2-7.2)	3.8 (2.3-5.5)	4.9 (2.7-6.1)	1
Detectable HBV-DNA <sup>†</sup>	95 (71.4)	17 (89.5)	10 (76.9)	NS
HBV-DNA <sup>‡</sup> , log <sub>10</sub> IU/mL*	5.2 (3.2-7.4)	4.6 (2.9-6.6)	6.6 (4.6-6.9)	NS
HBeAg-positive <sup>†</sup>	71 (53.4)	15 (79.0)	10 (76.9)	1
ALT, IU/L, <i>N</i> =161*	39 (26-68)	40 (23-64)	72 (54-145)	2,3
AST, IU/L, <i>N</i> =161*	33 (25-50)	28 (24-56)	66 (41-80)	2,3
F3-F4 fibrosis <sup>#</sup> , <i>N</i> =147 <sup>†</sup>	31 (26.5)	2 (10.5)	5 (38.5)	NS
LAM-resistant mutations, <i>N</i> =100 <sup>†</sup>	16 (20.3)	1 (9.1)	3 (30.0)	NS
<i>Precore</i> mutations, <i>N</i> =101 <sup>†</sup>	16 (20.5)	4 (30.8)	2 (20.0)	NS
HBV genotype, <i>N</i> =105 <sup>†</sup>				NS
A	54 (67.5)	9 (69.2)	8 (66.7)	
D	6 (7.5)	2 (15.4)	1 (8.3)	
E	6 (7.5)	2 (15.4)	1 (8.3)	
G	14 (17.5)	0 ( 0)	2 (16.7)	

\*Median (IQR).

† Number (%).

<sup>§</sup> Significance was determined using Kruskal-Wallis' test for continuous variables and Pearson's chi-square test or Fisher's exact test for categorical variables. Significant differences ( $p < 0.05$ ) between profile groups were indicated as follows: 1, sustained virological VR and transient PV; 2, sustained VR and LL-/HL-PV; 3, transient PV and LL-/HL-PV.

<sup>¥</sup> Among patients with detectable HIV-RNA or HBV-DNA viral loads.

<sup>#</sup> Estimated using the Fibrotest®.

Abbreviations: AIDS, acquired immune deficiency syndrome; ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMI, body mass index; cART, combined ART; HBV, hepatitis B virus; HBeAg, hepatitis B "e" antigen; HIV, human immunodeficiency virus; HL, high level; LAM, lamivudine; LL, low level; NS, no significant differences between groups; PV, persistent viremia; VR, virological response.

**Table 4.** Clinical and serological characteristics of hepatitis B virus replication profiles during follow-up.

Characteristics	Sustained VR (N=133)	Transient PV (N=19)	LL-/HL-PV (N=13)	p value <sup>§</sup>
Total follow-up, years*	8.1 (3.9-12.6)	13.7 (8.1-14.6)	4.1 (2.8-7.1)	1,2,3
HBV-DNA <sup>‡</sup>				
12-month change, log <sub>10</sub> IU/mL*	-2.57 (-4.82, -0.85)	-2.80 (-4.70, -0.92)	-4.28 (-4.80, -2.80)	2,3
24-month change, log <sub>10</sub> IU/mL*	-2.83 (-5.17, -1.10)	-1.58 (-4.80, -0.92)	-4.80 (-5.10, -2.80)	1,2,3
VR at 12 months <sup>†</sup>	86 (64.7)	10 (52.6)	7 (53.9)	NS
VR at 24 months <sup>†</sup>	110 (82.7)	11 (57.9)	9 (69.3)	1
VR at 36 months <sup>†</sup>	124 (93.2)	17 (89.5)	11 (84.6)	NS
HIV-RNA				
undetectable HIV VL in the last study visit <sup>†</sup>	123 (92.5)	19 (100.0)	10 (76.9)	NS
% undetectable HIV VLs during follow-up*	91.3 (80.0-100.0)	85.7 (52.9-91.3)	75.0 (58.3-88.2)	1,2
≥70% undetectable HIV VLs during follow-up <sup>†</sup>	111 (83.5)	11 (57.9)	8 (61.5)	1

Serological response				
HBeAg loss <sup>†‡</sup>	34 (25.6)	8 (42.1)	2 (15.4)	NS
HBeAg seroconversion <sup>†‡</sup>	13 (9.8)	1 (5.3)	1 (7.7)	NS
HBsAg loss <sup>†</sup>	11 (8.7)	2 (10.5)	0 ( 0)	NS
ALT				
Maximum decrease from baseline, IU/mL*	-12 (-39, -3)	-9 (-28, -2)	-84 (-92, -26)	1,2,3
Maximum increase from baseline, IU/mL*	9 (2-18)	12 (7-20)	51 (0-116)	1,2,3
Last follow-up visit, IU/mL	28 (21-36)	30 (18-39)	49 (32-78)	2,3
CD4 <sup>+</sup> cell count				
Last follow-up visit, IU/mL	540 (408-779)	460 (331-708)	408 (289-660)	1,2
Liver fibrosis <sup>#</sup>				
F3-F4 at last follow-up visit <sup>†</sup> , N=77	17 (28.8)	4 (36.4)	3 (42.9)	NS
Progression from F0-F1-F2 to F3-F4 <sup>&amp;†</sup> , N=69	5 (9.8)	4 (36.4)	0 (0.0)	1

\*Median (IQR).

<sup>†</sup>Number (%).

<sup>‡</sup>Among patients with detectable HBV-DNA at baseline.

<sup>#</sup>Among HBeAg-positive patients.

# Estimated using the Fibrotest®.

& From baseline to last follow-up visit, only in individuals with baseline F0-F1-F2 fibrosis.

<sup>§</sup>Significance was determined using Kruskal-Wallis' test for continuous variables and Pearson's chi-square test or Fisher's exact test for categorical variables. Significant differences ( $p < 0.05$ ) between profile groups were indicated as follows: 1, sustained virological VR and transient PV; 2, sustained VR and LL-/HL-PV; 3, transient PV and LL-/HL-PV.

Abbreviations: ALT, alanine aminotransferase; HBeAg, hepatitis B "e" antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HL, high level; LL, low level; PV, persistent viremia; VL, viral load; VR, virological response.

## Figure legends


### Figure 1.

Viral suppression during tenofovir (TDF)-treatment in (a) all patients and (b) different profiles of HBV replication; and HBV-DNA viral loads during TDF-treatment in patients with (c) sustained virological response (VR), (d) transient persistent viremia (PV), and (e) low-level/high-level persistent viremia (LL-/HL-PV). Individual levels are expressed as gray lines.

### Figure 2.


Cumulative probability of (a) hepatitis B 'e' antigen (HBeAg) and (b) hepatitis B surface antigen (HBsAg) seroclearance, according to different profiles of HBV replication.

**Figure 1.**



**Figure 2.**

(a)



(b)

